#Psychiatry

A large international genetic study released today strengthens the view that biology plays a meaningful role in who uses cannabis and who may develop problematic use. Researchers analyzed genetic data from more than 130,000 participants to identify regions of the genome associated with cannabis use and how often people use the drug. The work points to two specific genes, CADM2 and GRM3, as being related to lifetime cannabis use and frequency of use, respectively. Beyond those findings, the study reports dozens of additional gene signals and a broad pattern of genetic overlap with traits tied to psychiatric health, cognition, and physical well-being. The central message is clear: genetics helps shape early cannabis-related behaviors, which may influence who ends up facing cannabis use disorder, even as environment, policy, and personal choices steer the ultimate outcomes.

A wave of recent research and expert analyses suggests there is no consistent evidence that antidepressants cause violent behavior. Across multiple studies and real-world data, researchers emphasize that any risk appears extremely small and is often entwined with other factors such as the severity of illness, substance use, or rapid changes in mood. Medication is most beneficial when depression is properly treated, and clinicians stress that stopping antidepressants abruptly can raise risk in some individuals. For families in Thailand navigating mental health care, the message is clear: treat depression with evidence-based care, while staying vigilant about safety and overall well-being.

A Guardian reader’s question about electric shock therapy from the 1960s has become a focal point for a wider, evolving conversation in health research: how safe is electroconvulsive therapy today, what memory and cognitive effects does it leave behind, and what does that mean for patients and families in Thailand? The latest studies and reviews map a nuanced landscape. ECT remains a proven option for severe depression and certain other conditions, but its memory-related side effects, historical stigma, and ethical questions continue to spur discussion among clinicians, patients, and policymakers. For Thai readers, this evolution matters a great deal because access to mental health treatment, informed consent practices, and public understanding of ECT vary across the country. The personal story in question—told with candor about memory disruption, hospitalization, and the search for meaning decades later—reflects larger questions about how medicine can heal without unintentionally harming memory, identity, and dignity.

Cutting-edge research by scientific teams at Mount Sinai Hospital represents a fundamental breakthrough in understanding emotional regulation within the brain, potentially opening pathways to more precise, faster-acting psychiatric therapies for millions living with depression, anxiety, and related conditions throughout Thailand and globally. Recent study published in Science Advances reveals that a phospholipid fat molecule embedded deep within brain cell membranes acts as hidden regulatory partner to a vital mood-controlling receptor, providing unprecedented insights that could revolutionize mental health treatment approaches and offer new hope for patients who have not responded adequately to existing therapeutic options.

A cutting-edge discovery by research teams at Mount Sinai Hospital is rewriting what we know about how emotions are regulated in the brain, potentially pointing to new hope for millions living with depression, anxiety, and related conditions. A study published recently in Science Advances has found that a fat molecule called a phospholipid, deep within our brain cell membranes, acts as a hidden “co-pilot” to a vital mood-regulating receptor. This fundamental insight could pave the way for more precise, faster-acting psychiatric therapies—with implications for mental health care in Thailand and across the world (neurosciencenews.com).

A collaborative study by Thai researchers and international partners has unveiled a fundamental mechanism behind emotional regulation in the brain, paving the way for faster, more targeted psychiatric therapies. Published in Science Advances, the work identifies a phospholipid molecule hidden within brain cell membranes that partners with a key mood receptor, offering fresh avenues for treating depression, anxiety, and related conditions in Thailand and beyond.

This breakthrough could especially benefit patients who do not respond well to current treatments. The findings come at a time when Thailand faces a rising mental health challenge, underscoring the need for therapies that consider both biological and cultural factors in Thai society.

A recent investigative piece, “Out of Sight, Out of Mind” by Bonnie Schell, published on Mad in America, is reigniting discussion about how modern societies—particularly the United States—manage visibly unhoused and mentally ill populations. The article, released on July 28, 2025, details not only current US policies involving forced removals of homeless encampments but also traces the roots of these actions to a centuries-old history of social segregation, institutionalization, and medicalization. For Thai readers, this global narrative fuels reflection on how societies—perhaps even Thailand itself—balance public order, health, policy ethics, and human dignity.

A compelling examination of how societies treat visibly unhoused people and individuals with mental illness reveals a long-standing tension between public order and human dignity. The piece, published mid-2025, traces policies that favor removal over root-cause solutions and situates them within a centuries-old pattern of social segregation and medicalization. For Thai readers, it invites reflection on how Thailand can balance safety, ethics, and compassion in public policy.

The article opens with current events where authorities clear public spaces ahead of major national activities. It highlights a familiar pattern in many places: reducing the visibility of poverty and mental illness through removal and coerced treatment rather than investing in living-wage jobs, affordable housing, and community-based mental health care. This approach is linked to a broader historical thread that traces back to ancient thinkers who advocated removing stigmatized individuals from public view, illustrating how urban policy has long shaped inclusion or exclusion.

A groundbreaking study from Denmark, recently published in The Lancet Psychiatry, offers new understanding of family patterns in mental health disorders. The research confirms that relatives of individuals with mental illness face a higher risk themselves—yet, surprisingly, most cases still occur among people with no prior family history. This finding is poised to reshape mental health awareness and prevention strategies not just globally but also in Thailand, where mental health remains a growing public health priority.

A major Danish study published in The Lancet Psychiatry reveals how mental disorders cluster in families, while also showing that most cases occur without a known family history. The findings carry important implications for mental health awareness and prevention in Thailand, where well-being has become a national priority.

Mental disorders such as depression, anxiety, addiction, schizophrenia, and personality disorders affect millions worldwide and are increasingly part of Thailand’s public health dialogue. Led by researchers at Aarhus University’s National Centre for Register-Based Research, the study is among the largest of its kind. Over fifty years, scientists tracked more than 3 million people, linking registry data to map patterns within families. This extensive approach yields robust statistics that can inform policy and practice in Thailand and beyond.

A well-known British comedian recently described a life-changing moment: after decades of severe depression, joy returned within seconds once he learned he has adult ADHD. He called the experience transformative, even magical. The personal story aligns with a growing body of research showing many adults carry undiagnosed ADHD and how it intersects with chronic depression.

In Thailand, mental health is increasingly prioritized, with rising rates of depression and anxiety especially in Bangkok’s urban environment. Many adults experience low mood and motivation that are often misread as personal fault. Global research indicates a notable portion of adults treated for depression may actually have undiagnosed ADHD, a condition once considered only a childhood issue but now recognized as a lifelong challenge.

In a striking recent interview, a well-known British comedian revealed that after nearly three decades living under the shadow of severe depression, his mood and capacity for joy improved within seconds of learning he had adult ADHD—a moment he described as transformative and almost magical. While this story (reported by The Guardian) is deeply personal, it highlights a growing body of research underscoring the hidden prevalence of undiagnosed ADHD among adults, and its strong association with chronic depression. For many, especially in societies where mental health remains stigmatized, this account may offer new hope—and vital information about alternative pathways to recovery.

A landmark international study challenges the idea that mental illness runs mainly through families. Led by researchers in Denmark, the analysis used health records for more than 3 million people and found that most serious conditions—such as schizophrenia, bipolar disorder, and depression—occur in individuals without close family history. The Lancet Psychiatry published the findings, which emphasize environmental factors and random variation as substantial contributors. The result has clear implications for Thailand’s evolving approach to mental health care.

In a landmark study challenging widespread beliefs about heredity and mental health, researchers have found that the majority of cases of serious mental illnesses such as schizophrenia, bipolar disorder, and depression arise in individuals with no close family history of these conditions. The research, covering data from over 3 million people, calls for a shift in how mental health is understood and addressed both globally and within Thailand’s evolving mental health landscape (Neuroscience News).

Groundbreaking research into psychedelic compounds is shedding new light on how these substances might revolutionize the treatment of mental health disorders, promising innovative alternatives for people in Thailand and across the globe. A suite of recent studies explores the biological and psychological mechanisms by which psychedelics—including psilocybin (found in magic mushrooms), lysergic acid diethylamide (LSD), ayahuasca, and MDMA—modulate brain circuits, emotions, and cognition with potentially enduring therapeutic benefits. These advances herald a growing shift from anecdotal and early-phase examinations of psychedelics toward a more rigorous, mechanistic understanding crucial for clinical application.

A newly published review in JAMA Psychiatry has sparked controversy among mental health experts, raising concerns that it significantly underestimates the risks faced by long-term users of antidepressants when they attempt to discontinue their medication. The debate centers on the review’s focus on short-term, industry-funded studies and has important implications for millions worldwide, including a growing cohort of patients in Thailand who rely on antidepressant therapy.

Antidepressant withdrawal — the range of physical and psychological symptoms experienced when stopping or reducing dosage — has come under increased scrutiny as more people use these medications for extended periods. While previous medical guidelines, such as those from the UK’s National Institute for Health and Care Excellence (NICE), described withdrawal as “brief and mild,” recent scrutiny has revealed a more complex picture, particularly for long-term users. The new JAMA Psychiatry review, authored in part by academics with ties to pharmaceutical companies, concludes that withdrawal symptoms from antidepressants are generally not clinically significant for most users, especially those on the medication for only eight to twelve weeks. Its analysis, based on eleven trials — the vast majority of which involved short-term use — found slightly more withdrawal symptoms in those stopping antidepressants than in placebo groups, but the authors attribute much of this to the “nocebo effect” (the power of negative expectations to trigger adverse symptoms) rather than to withdrawal itself.

A recent review in JAMA Psychiatry has reignited debate among mental health professionals about withdrawal risks for people who discontinue antidepressants, especially after extended use. This discussion is timely for Thailand, where more patients rely on long‑term therapy and guidelines continue to adapt to evolving evidence.

Antidepressant withdrawal involves a spectrum of physical and psychological symptoms that can occur when reducing or stopping medication. Earlier guidelines, including NICE in the UK, described withdrawal as brief and mild. Newer research paints a more nuanced picture, particularly for long‑term users. The JAMA Psychiatry review analyzed eleven trials, most of which examined short‑term use, and found slightly more withdrawal symptoms in those stopping antidepressants than in placebo groups. The authors attributed much of this to the nocebo effect—the power of negative expectations to trigger symptoms—rather than withdrawal itself.

A prominent psychiatrist has expressed deep remorse over his role in transforming the landscape of autism in America—a change that saw US autism rates leap from 1 in 2,000 children in the 1980s to approximately 1 in 31 today. The surge, he says, is largely attributable to expanded diagnostic criteria introduced in the 1990s and further broadened in the 2010s, with far-reaching consequences for families, public health policy, and social attitudes across the globe—including in Thailand.

A new study advances our understanding of how the brain tells apart what we imagine from what we actually see. The research, conducted by a team at University College London and published in Neuron, identifies the fusiform gyrus as a key player in this reality-imagination divide. The findings carry relevance for mental health, technologies, and our broader grasp of perception.

Thai readers have long grappled with distinguishing fact from fiction, from traditional notions of illusion to modern concerns about digital misrepresentation. This study translates those ancient questions into measurable biology, showing how certain brain processes can blur the line between real experiences and vivid internal imagery. For Thailand’s growing population affected by conditions such as schizophrenia, the work offers new avenues for diagnosis, understanding, and potential intervention.

In a pioneering new study, neuroscientists have traced the precise brain mechanisms that empower us to tell the difference between what we imagine and what we actually see—an ability fundamental to understanding our own experience and, when disrupted, central to psychiatric conditions like schizophrenia. The research, published this month in Neuron by a team at University College London (UCL), pinpoints the fusiform gyrus—a visual processing region of the brain—as a critical player in this reality-imagination divide, offering profound implications for mental health, technology, and our understanding of human perception (Neuroscience News).

A groundbreaking new philosophical analysis is challenging long-held psychiatric beliefs about delusion, urging the field to reconsider whether so-called “madness” is truly a sign of dysfunction or evidence of meaningful, adaptive strategy. The latest work, highlighted in a recent article on Mad in America and anchored in research from the European Journal of Analytic Philosophy, proposes that delusions may be better understood not as isolated symptoms of mental disorder, but as purposeful responses to overwhelming distress—responses that are systematically misunderstood, and unjustly marginalized, by conventional psychiatric practice (Madin America; European Journal of Analytic Philosophy).

A bold philosophical analysis is challenging decades of psychiatric thinking about delusion. It argues that madness might reflect meaningful, adaptive strategies rather than mere dysfunction. The latest work, discussed in a recent Mad in America feature and drawing on European Journal of Analytic Philosophy insights, suggests delusions may be purposeful responses to extreme distress. These beliefs are often misunderstood and marginalized by standard psychiatric practice, and a strategy-focused view could help reduce stigma in Thailand and beyond.

A senior psychiatry researcher from a leading U.S. medical center, who also lives with bipolar disorder, recently shared her diagnosis, daily management, and cutting-edge treatment developments on a popular science podcast. Her unique perspective—balancing scientist and patient roles—offers both human insight and scientific clarity about a condition that remains stigmatized in many societies, including Thailand.

For Thai readers, the topic hits close to home. Mental health care in Thailand continues to improve but still faces stigma, gaps in access, and shortages of trained professionals, particularly in rural areas. As global research advances, Thai families, educators, and health officials can learn from international experiences to strengthen local responses and reduce barriers to care.

Bipolar disorder, a complex mood disorder marked by dramatic oscillations between depression and mania, affects an estimated 40 million people worldwide. It is a condition that not only tests individuals’ emotional resilience but also challenges the medical community in its search for effective, personalized treatments. In a recent episode of NPR’s podcast Short Wave, a renowned psychiatry professor from Johns Hopkins School of Medicine—herself living with bipolar disorder—opened up about her diagnosis, daily management, and the latest advancements in treatment. Her dual role as scientist and patient offers a rare, deeply personal, and scientific insight into a condition that remains stigmatized and often misunderstood in many societies, including Thailand.